Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection

Open access
Rosenke, Kyle, Meade-White, Kimberly, Letko, Michael, Clancy, Chad, Hansen, Frederick, Liu, Yanan, Okumura, Atsushi, Tang-Huau, Tsing-Lee, Li, Rong, Saturday, Greg, Feldmann, Friederike, Scott, Dana, Wang, Zhongde, Munster, Vincent, Jarvis, Michael A., Feldmann, Heinz · 2020 · Emerging Microbes & Infections

Published version of a preprint

Abstract

Following emergence in late 2019, SARS-CoV-2 rapidly became pandemic and is presently responsible for millions of infections and hundreds of thousands of deaths worldwide. There is currently no approved vaccine to halt the spread of SARS-CoV-2 and only very few treatment options are available to manage COVID-19 patients. For development of preclinical countermeasures, reliable and well-characterized small animal disease models will be of paramount importance. Here we show that intranasal inoculation of SARS-CoV-2 into Syrian hamsters consistently caused moderate broncho-interstitial pneumonia, with high viral lung loads and extensive virus shedding, but animals only displayed transient mild disease. We determined the infectious dose 50 to be only five infectious particles, making the Syrian hamster a highly susceptible model for SARS-CoV-2 infection. Neither hamster age nor sex had any impact on the severity of disease or course of infection. Finally, prolonged viral persistence in interleukin 2 receptor gamma chain knockout hamsters revealed susceptibility of SARS-CoV-2 to adaptive immune control. In conclusion, the Syrian hamster is highly susceptible to SARS-CoV-2 making it a very suitable infection model for COVID-19 countermeasure development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/22221751.2020.1858177

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 31

  1. 10.1016/S0140-6736(20)30211-7 · DOI · Paper page
  2. 10.1001/jama.2020.1585 · DOI · Paper page
  3. 10.1016/j.ijantimicag.2020.105949 · DOI · Paper page
  4. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–1836.
  5. Ali MJ, Hanif M, Haider MA, et al. Treatment options for COVID-19: a review. Front Med (Lausanne). 2020;7(480).
  6. 10.3851/IMP3368 · doi:10.3851/imp3368
  7. 10.1101/2020.05.14.096727 · DOI
  8. 10.1016/j.chom.2020.03.023 · DOI · Paper page
  9. 10.1016/S2666-5247(20)30089-6 · DOI · Paper page
  10. 10.1126/science.abb7015 · DOI · Paper page
  11. 10.1038/s41586-020-2312-y · DOI · Paper page
  12. 10.1073/pnas.2009799117 · DOI · Paper page
  13. 10.1101/2020.05.02.073411 · DOI
  14. 10.1038/s41586-020-2342-5 · DOI · Paper page
  15. 10.1016/j.cell.2020.06.011 · DOI · Paper page
  16. 10.1101/2020.05.27.118893 · DOI
  17. 10.1128/JVI.01702-06 · DOI · Paper page
  18. 10.1016/j.chom.2020.05.020 · DOI · Paper page
  19. 10.1007/s13238-020-00767-x · DOI
  20. 10.3201/eid2606.200516 · DOI · Paper page
  21. 10.1242/dmm.044602 · DOI
  22. 10.1093/oxfordjournals.aje.a118408 · DOI · Paper page
  23. 10.2807/1560-7917.ES.2020.25.3.2000045 · DOI · Paper page
  24. 10.1038/s41586-020-2012-7 · DOI · Paper page
  25. 10.1101/2020.06.29.177154 · doi:10.1101/2020.06.29.177154
  26. 10.1016/j.immuni.2019.03.028 · DOI · Paper page
  27. Allenspach E, Rawlings DJ, Scharenberg AM, et al. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, editor. X-linked severe combined immunodeficiency. Seattle, WA: GeneReviews((R)); 1993.
  28. 10.3390/ijms21082948 · DOI · Paper page
  29. Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34(2).
  30. 10.3345/cep.2020.00493 · DOI · Paper page
  31. 10.1016/j.cell.2020.05.027 · DOI · Paper page

Cited by

See all 229

Metadata

Authors
Rosenke, K., Meade-White, K., Letko, M., Clancy, C., Hansen, F., Liu, Y., Okumura, A., Tang-Huau, T.-L., Li, R., Saturday, G., Feldmann, F., Scott, D., Wang, Z., Munster, V., Jarvis, M. A., & Feldmann, H.
Venue
Emerging Microbes & Infections
Published
2020-01
Volume
9
Issue
1
Pages
2673-2684
ISSN
2222-1751 (ISSN-L)
OpenAlex
W3107525025
Cited by
229
References
9
FWCI
5.43
Type
journal article
Language
en
Open access
gold
Funders
  • National Institutes of Allergy and Infectious Diseases
  • National Institutes of Health
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. https://app.cochat.ai/papers/10.1080/22221751.2020.1858177
The paper
Rosenke, K., Meade-White, K., Letko, M., Clancy, C., Hansen, F., Liu, Y., Okumura, A., Tang-Huau, T.-L., Li, R., Saturday, G., Feldmann, F., Scott, D., Wang, Z., Munster, V., Jarvis, M. A., & Feldmann, H. (2020). Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerging Microbes & Infections. https://doi.org/10.1080/22221751.2020.1858177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.